Kamal Abi Mosleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kamal Abi Mosleh has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Omar M. Ghanem
Department of Surgery, Mayo Clinic, Rochester, USA
15 shared publications - Noura Jawhar
Department of Surgery, Mayo Clinic, Rochester, Minnesota
7 shared publications - Barham K. Abu Dayyeh
Mayo Clinic, Rochester, USA
4 shared publications Karl Hage
Department of Surgery, Mayo Clinic, Rochester, MN, 55905, USA
4 shared publications- Benjamin Clapp
Department of Surgery Texas Tech University Health Sciences Center El Paso Texas USA
3 shared publications Hugh Babineau
Department of Surgery, The University of Texas Health Science Center at Tyler, Tyler, Texas
3 shared publications
Latest Publications
- 17 April 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22 (7) , e24-e25
Comment on: Current trends in reoperative bariatric surgery using MBSAQIP database 2020-2023
- 17 April 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22 (7) , e24-e25
Comment on: Current trends in reoperative bariatric surgery using MBSAQIP database 2020-2023
- 14 March 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22 (7) , e17-e18
Comment on: Benchmarking weight loss and survival benefits after gastric bypass: a long-term cohort study
- 14 March 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 22 (7) , e17-e18
Comment on: Benchmarking weight loss and survival benefits after gastric bypass: a long-term cohort study
- 7 March 2025
- Published by Springer Nature
- p. 113-122
Laparoscopic Median Arcuate Ligament Release: Technical Aspects for a Safe and Effective Procedure
- 7 March 2025
- Published by Springer Nature
- p. 113-122
Laparoscopic Median Arcuate Ligament Release: Technical Aspects for a Safe and Effective Procedure
- 19 February 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (3) , 701-714
Long-Term Safety and Efficacy Profile of Bariatric Surgery in Patients Classified with ASA IV Status
Introduction Metabolic and bariatric surgery (MBS) is a safe and effective treatment option to reduce weight and manage obesity-related medical conditions in patients with obesity. However, due to limited data, there is uncertainty regarding the short-, mid-, and long-term safety and efficacy profile of MBS in patients with a preoperative ASA IV status. Methods A single-center retrospective cohort study was performed on patients with ASA IV status who underwent sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD-DS) between 2008 and 2020. Data collected included operative details; postoperative complications at 30 days, 90 days, and beyond 90 days; BMI changes; and resolution of obesity-related comorbidities at 0, 6, 12, 24, 48, and 60 months postoperatively. Results Among 131 ASA class IV patients, 43 patients underwent SG (32.8%), 66 patients underwent RYGB (50.4%), and 22 patients underwent BPD-DS (16.8%). The greatest %TWL occurred in the BPD-DS cohort (39.5%) at 24 months post-op followed by the RYGB (32.5%) and SG (20.7%) cohorts (p < 0.001). The overall major 30-day complication rate was 8.4% (n = 11/131), while the overall major 90-day complication rate within the cohort was 6.9% (n = 9/131). The overall major late (> 90 days) complication rate was found to be 14.5% (n = 19/131). Conclusions Our study demonstrated that MBS is relatively safe and effective in ASA IV patients in the short-, mid-, and long-term. Accordingly, careful procedure selection is required in this patient population. Further long-term studies are needed to support our findings.
- 19 February 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (3) , 701-714
Long-Term Safety and Efficacy Profile of Bariatric Surgery in Patients Classified with ASA IV Status
Introduction Metabolic and bariatric surgery (MBS) is a safe and effective treatment option to reduce weight and manage obesity-related medical conditions in patients with obesity. However, due to limited data, there is uncertainty regarding the short-, mid-, and long-term safety and efficacy profile of MBS in patients with a preoperative ASA IV status. Methods A single-center retrospective cohort study was performed on patients with ASA IV status who underwent sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD-DS) between 2008 and 2020. Data collected included operative details; postoperative complications at 30 days, 90 days, and beyond 90 days; BMI changes; and resolution of obesity-related comorbidities at 0, 6, 12, 24, 48, and 60 months postoperatively. Results Among 131 ASA class IV patients, 43 patients underwent SG (32.8%), 66 patients underwent RYGB (50.4%), and 22 patients underwent BPD-DS (16.8%). The greatest %TWL occurred in the BPD-DS cohort (39.5%) at 24 months post-op followed by the RYGB (32.5%) and SG (20.7%) cohorts (p < 0.001). The overall major 30-day complication rate was 8.4% (n = 11/131), while the overall major 90-day complication rate within the cohort was 6.9% (n = 9/131). The overall major late (> 90 days) complication rate was found to be 14.5% (n = 19/131). Conclusions Our study demonstrated that MBS is relatively safe and effective in ASA IV patients in the short-, mid-, and long-term. Accordingly, careful procedure selection is required in this patient population. Further long-term studies are needed to support our findings.
- 1 November 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (4) , 382-388
Assessment of predictors of acute kidney injury and progression to chronic kidney disease following bariatric surgery
- 1 November 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (4) , 382-388
Assessment of predictors of acute kidney injury and progression to chronic kidney disease following bariatric surgery
- 31 July 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (10) , 1613-1621
Shedding more than weight: Metabolic and bariatric surgery and the journey to insulin independence in insulin-treated type 2 diabetes
- 31 July 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (10) , 1613-1621
Shedding more than weight: Metabolic and bariatric surgery and the journey to insulin independence in insulin-treated type 2 diabetes
- 27 June 2024
- Published by Wiley in Clinical Obesity
- Vol. 14 (6) , e12689
Impact of metabolic and bariatric surgery on weight loss and insulin requirements in type 1 and insulin‐treated type 2 diabetes
Summary: Metabolic and Bariatric Surgery (MBS) is effective in improving metabolic outcomes and reducing weight in patients with obesity and diabetes, with less explored benefits in type 1 diabetes (T1D). This study aimed to evaluate the impact of MBS on weight loss and insulin requirements in T1D patients compared to insulin‐treated type 2 diabetes (T2D) patients over a 5‐year period. This retrospective analysis included patients who underwent primary sleeve gastrectomy (SG) or Roux‐en‐Y gastric bypass (RYGB) with a confirmed preoperative diagnosis of either T1D or insulin‐treated T2D. Primary endpoints focusing on weight loss and secondary outcomes assessing changes in insulin dosage and glycemic control. After 5 years, weight loss was similar across groups, with total weight loss at 14.2% for T1D and 17.6% for insulin‐treated T2D in SG, and 22.6% for T1D vs. 26.8% for insulin‐treated T2D in RYGB. Additionally, there was a significant reduction in median daily insulin doses from 140.5 units at baseline to 77.5 units at 1 year postoperatively, sustained at 90 units at 5 years. The differential impact of MBS procedure was also highlighted, where RYGB patients showed a more pronounced and enduring decrease in insulin requirements compared to SG.
- 27 June 2024
- Published by Wiley in Clinical Obesity
- Vol. 14 (6) , e12689
Impact of metabolic and bariatric surgery on weight loss and insulin requirements in type 1 and insulin‐treated type 2 diabetes
Summary: Metabolic and Bariatric Surgery (MBS) is effective in improving metabolic outcomes and reducing weight in patients with obesity and diabetes, with less explored benefits in type 1 diabetes (T1D). This study aimed to evaluate the impact of MBS on weight loss and insulin requirements in T1D patients compared to insulin‐treated type 2 diabetes (T2D) patients over a 5‐year period. This retrospective analysis included patients who underwent primary sleeve gastrectomy (SG) or Roux‐en‐Y gastric bypass (RYGB) with a confirmed preoperative diagnosis of either T1D or insulin‐treated T2D. Primary endpoints focusing on weight loss and secondary outcomes assessing changes in insulin dosage and glycemic control. After 5 years, weight loss was similar across groups, with total weight loss at 14.2% for T1D and 17.6% for insulin‐treated T2D in SG, and 22.6% for T1D vs. 26.8% for insulin‐treated T2D in RYGB. Additionally, there was a significant reduction in median daily insulin doses from 140.5 units at baseline to 77.5 units at 1 year postoperatively, sustained at 90 units at 5 years. The differential impact of MBS procedure was also highlighted, where RYGB patients showed a more pronounced and enduring decrease in insulin requirements compared to SG.
- 12 June 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 237, 115796
A comprehensive analysis of health care Inequities in randomized clinical trials following bariatric surgeries
- 12 June 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 237, 115796
A comprehensive analysis of health care Inequities in randomized clinical trials following bariatric surgeries